P Trechot1, J-L Schmutz. Show Affiliations » 1. Service de pharmacovigilance, hôpital Central, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy cedex, France.
Abstract
Entities: Disease
Mesh： See more » Adrenal Cortex Hormones/therapeutic useAgedAlanine/adverse effectsAlanine/analogs & derivativesAlanine/pharmacologyAlanine/therapeutic useAlzheimer Disease/complicationsAlzheimer Disease/drug therapyAmyloid Precursor Protein Secretases/antagonists & inhibitorsAzepines/adverse effectsAzepines/pharmacologyAzepines/therapeutic useClinical Trials, Phase III as TopicDrug Therapy, CombinationEarly Termination of Clinical TrialsFemaleHumansKeratinocytes/drug effectsKeratinocytes/metabolismMemantine/therapeutic useModels, BiologicalNootropic Agents/adverse effectsNootropic Agents/pharmacologyNootropic Agents/therapeutic usePhenylcarbamates/therapeutic usePsoriasis/chemically inducedPsoriasis/complicationsPsoriasis/drug therapyReceptors, Notch/physiologyRivastigmineSignal Transduction/drug effects
Substances： See more » Adrenal Cortex HormonesAzepinesN2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamideNootropic AgentsPhenylcarbamatesReceptors, NotchAmyloid Precursor Protein SecretasesAlanineRivastigmineMemantine
Year: 2013 PMID： 24090904 DOI： 10.1016/j.annder.2013.06.003
Source DB: PubMed Journal: Ann Dermatol Venereol ISSN： 0151-9638 Impact factor: 0.777